Prevention of COVID-19
Conditions
Interventions
Inoculate once intramuscularly (usually in the deltoid muscle of the upper arm) at the prescribed dose as per the prescribing information.
Sponsors
Koga Michiko
Eligibility
Inclusion criteria
Inclusion criteria: 1, Individuals aged 18 or older who are in good health, have previously received a COVID-19 vaccine, and can provide documentation of their vaccination history at the time of consent. 2, For those with a history of COVID-19 infection, the infection date must be identifiable, and at least one month must have passed since the last COVID-19 infection. 3, At least six months must have passed since the last COVID-19 vaccination. 4, Individuals who are able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1, Individuals presenting with an evident fever at the vaccination. 2, Individuals suffering from a severe acute illness. 3, Individuals who have experienced febrile upper respiratory tract infections within one month before vaccination. 4, Individuals with a history of severe hypersensitivity to any vaccine component. 5, Individuals in any other condition deemed unsuitable for vaccination. 6, Any other individuals whom the principal investigator considers ineligible for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 Neutralizing Antibody Titer (Omicron Variant JN-1) Before and One Month After Vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Other SARS-CoV-2 Neutralizing Antibody Titers and Additional Immune Responses (T Cells, B Cells) | — |
Contacts
Public ContactKono Minako
IMSUT Hospital, The Institute of Medical Science, The Univers ity of Tokyo
Outcome results
None listed